- Methodology article
- Open Access
Identification of cardiac malformations in mice lacking Ptdsrusing a novel high-throughput magnetic resonance imaging technique
© Schneider et al; licensee BioMed Central Ltd. 2004
- Received: 14 October 2004
- Accepted: 22 December 2004
- Published: 22 December 2004
Congenital heart defects are the leading non-infectious cause of death in children. Genetic studies in the mouse have been crucial to uncover new genes and signaling pathways associated with heart development and congenital heart disease. The identification of murine models of congenital cardiac malformations in high-throughput mutagenesis screens and in gene-targeted models is hindered by the opacity of the mouse embryo.
We developed and optimized a novel method for high-throughput multi-embryo magnetic resonance imaging (MRI). Using this approach we identified cardiac malformations in phosphatidylserine receptor (Ptdsr) deficient embryos. These included ventricular septal defects, double-outlet right ventricle, and hypoplasia of the pulmonary artery and thymus. These results indicate that Ptdsr plays a key role in cardiac development.
Our novel multi-embryo MRI technique enables high-throughput identification of murine models for human congenital cardiopulmonary malformations at high spatial resolution. The technique can be easily adapted for mouse mutagenesis screens and, thus provides an important new tool for identifying new mouse models for human congenital heart diseases.
- Congenital Heart Disease
- Outflow Tract
- Ventricular Septal Defect
- Cardiac Malformation
- Mutagenesis Screen
Congenital malformations are a major cause of death in childhood, and are typically characterized by lesions that do not compromise fetal survival. For instance, congenital heart disease (CHD) typically consists of lesions such as ventricular and atrial septal defects, which are compatible with fetal hemodynamics . Although human genetic studies have identified some genes that cause congenital cardiac malformations, the molecular and developmental mechanisms underlying most of these defects remain largely unknown. Despite the high incidence of CHD (~1% of live births), only a handful of genes have been identified that when mutated, result in congenital heart disease [2–4].
The mouse is a particularly good model for studying mechanisms of cardiac diseases as its anatomy and development resembles that of the human more closely than any other genetically tractable organism. Importantly, the mouse is amenable to genotype-driven approaches such as transgenic knockouts of defined candidate genes , genome wide mutagenesis approaches using gene-trap  or transposon insertion screens , and high-throughput phenotype-driven screens that rely, for instance, on N-ethyl-N-nitrosourea (ENU) mutagenesis [8, 9]. However, high-throughput cardiovascular genomic approaches in the mouse have been hampered by the paucity of phenotyping tools that allow efficient identification of complex cardiac malformations. As mouse embryos are opaque, late developmental defects are particularly difficult to identify. For instance, cardiac septal defects or outflow tract abnormalities can only be confidently identified after 14.5 days post coitum (dpc) when cardiac and outflow tract septation are completed in normal embryos. The identification of malformations in late gestation embryos typically relies on serial histological sectioning, which is extremely labor intensive. Furthermore, this often results in the irretrievable loss of 3D information, which is essential for the interpretation of complex cardiac malformations. In addition, standard pathological analysis is not amenable to high-throughput phenotype screening protocols that are required for any mutagenesis screen aiming at the functional dissection of the developmental biology of cardiac diseases. Therefore, new technological approaches must be harnessed that allow an efficient phenotyping of heart defects and also of subtle cardiac abnormalities that are at danger of being overseen in traditional histopathology screens. This is even more important in the light of upcoming new endeavors in functional mouse genome annotation . Currently, new large-scale mouse mutagenesis screens are being set up in the US and in Europe that aim to produce heritable mutations in every gene in the mouse genome [11–13]. To make full use of these new mouse mutant resources more precise and efficient phenotyping methods are urgently needed [12–14]. The success of genome wide saturation mutagenesis screens depends therefore on improved phenotyping, and new high-resolution imaging approaches for mouse mutants are one of the most important which need to be established.
We previously reported the development of fast gradient-echo MRI of single mouse embryos [15–17]. This resulted in the acquisition of a 3D dataset in under 9 hours, with an experimental image resolution of 25 × 25 × 26 μm/voxel. We showed that MRI is capable of accurately identifying normal embryonal structures, and cardiac and adrenal malformations in knockout mouse embryos, and we have validated this technique by performing in depth histological examinations of imaged embryos [15–17]. These experiments showed that single-embryo MRI could correctly identify all cardiac lesions (atrial septal defects, ventricular septal defects, outflow tract defects such as double-outlet right ventricle, and aortic arch defects) except those under 20 μm – which is below the resolution of the MRI technique. As this method images single embryos in overnight runs, it still lacks the throughput required for phenotype-driven mutagenesis screens. For instance, in a typical recessive ENU mutagenesis screen, to screen 50 ENU mutant lines using a 3-generation breeding scheme would require the analysis of ~1200 embryos . We now report the development of a method of imaging up to 32 embryos simultaneously in a single unattended overnight run, at high spatial resolution. Allowing ~30 minutes per embryo, the analysis of 1200 embryos would take 75 working days for a single trained individual. We show that this high-throughput multi-embryo MRI technique can be used to rapidly identify unsuspected embryonal cardiac and visceral malformations. Using this technique we could identify a novel, and hitherto unsuspected role for the phosphatidylserine receptor (Ptdsr) in controlling ventricular septal, outflow tract and pulmonary artery development. In addition, we found thymus hypoplasia in Ptdsr-deficient embryos. These findings suggest that a novel Ptdsr-mediated pathway is required for cardiac and thymus development.
Sensitivity and specificity of multi-embryo imaging
Cardiac malformations in mice lacking Ptdsr
Utility of MRI in identifying mouse models of human malformations
Our results show that it is possible to efficiently identify and quantitate relatively subtle cardiac and visceral malformations in late gestation mouse embryos using multi-embryo MRI. We have deliberately optimized our technique at late gestation in order to identify those congenital defects that allow survival through most of gestation. Importantly, these defects resemble human congenital malformations, and would provide mouse models for the study of these diseases. Our method represents a simpler alternative to the multi-coil approach published recently [27, 28] in which up to eight fixed mouse embryos were imaged simultaneously, with a resolution of 200 μm. In comparison, the multi-embryo method described here has a higher experimental resolution of 43 μm. Notably, it requires substantial developmental and financial effort to equip an experimental MR-system with multiple coil and receive capability.
Role of MRI in investigating murine embryonal or perinatal lethality
Many mouse gene knockouts display late gestational lethality, but incomplete analysis and loss of 3D information consequent to histological sectioning, results in major developmental malformations being frequently missed. As shown here, Ptdsr-/- embryos on a C57BL/6J background develop heart defects. This was not noted in recent reports [22, 24], and emphasizes the need not only for completely examining several mutant embryos, but also repeating these examinations in different genetic backgrounds. A major advantage of MRI is the ability to easily ship fixed embryos from referring laboratories to the laboratory that performs the MRI analysis. This minimizes the expense of animal relocation, re-derivation, and breeding required to generate the embryos, and significantly reduces animal experimentation.
Role of MRI in high-throughput phenotype driven screens
MRI screens performed at late gestation would be expected to identify genes that affect later aspects of development, and identify hypomorphic and haploinsufficient alleles of genes that affect earlier steps of development. Published data from genome-wide ENU mutagenesis screens in the mouse indicate that ~30% progeny carry a heritable recessive phenotype, making 3-generation recessive screens the method of choice for identifying developmental malformations . At least 24 3rd generation progeny per 1st generation mutant are typically screened, resulting in a >78% probability of identifying at least one fully penetrant recessive homozygous mutant. A typical recessive screen (e.g. 50 – 100 first generation mutants per year) would require the analysis of ~1200 – 2400 embryos per year. Our results show that multi-embryo MRI is eminently suitable for such throughput. Although, screening of 32 embryos overnight requires typically about 16 hours of data analysis, multi-embryo MRI mutagenesis screens can be easily performed at a reasonable scale if multiple operators analyze the data in parallel. As the data are permanently stored on DVDs, and can be analyzed easily by commercially available software, they can be without difficulty disseminated to specialists for further and more detailed analysis. Another powerful application of multi-embryo MRI will likely be the investigation and screening of potentially teratogenic drugs.
Functional role of Ptdsrin heart development
Our results presented here indicate a new, and hitherto unsuspected role for the phosphatidylserine receptor in controlling ventricular septal, outflow tract, pulmonary artery, and thymus development. This finding suggests that a novel Ptdsr-mediated pathway is required for cardiac and thymus development. Recently, we have demonstrated that in contrast to previously reported hypothetical Ptdsr functions, the Ptdsr protein is not required for the clearance of apoptotic cells . Moreover, detailed analysis of apoptosis induction and apoptotic cell clearance in Ptdsr+/+ and Ptdsr-/- embryos during heart development did not reveal any difference in the number and location of apoptotic cells between the genotypes (J.B., A.D.G. and A.L. unpublished observations). This further excludes that Ptdsr has any function in apoptotic cell clearance and points to other developmental mechanisms that are affected by Ptdsr ablation. The neural crest plays an important role in the development of the cardiac outflow tract, aortic arches, and the thymus . As Ptdsr-deficient embryos lack intestinal ganglia  which are also derived from the neural crest, these results suggest that Ptdsr-/- mice may have an underlying neural crest defect. Importantly, dysfunction of these Ptdsr-mediated pathways during development could also potentially result in heart defects in humans.
Our results validate the utility of multi-embryo MRI for high-throughput identification of murine models for human congenital cardiac malformations, and using this technique we have shown that Ptdsr is essential for normal cardiac development. Further experiments are needed to define exactly in which pathways Ptdsr is involved during heart development. We expect that multi-embryo MRI will be an important technology for future phenotype-driven mouse mutagenesis screens. The technology can be easily implemented at standard MRI imaging centers, thus allowing by collaboration with individual researchers or mouse mutagenesis centers, a high-throughput functional genetic dissection of mechanisms underlying cardiac development and congenital heart diseases.
Embryos were fixed in 4% paraformaldehyde at 4°C for ~1 week, and then embedded in 1% agarose (Seakem) containing 2 mM gadolinium-diethylenetriamine pentaacetic anhydride (Gd-DTPA, Magnevist, Schering UK) in 28 mm nuclear magnetic resonance tubes (Figure 1). The left forelimb was removed from each embryo to facilitate the identification of the left side. In addition, embryos had other limbs and/or tails removed before embedding so that each embryo in a given layer (of four embryos) could be unequivocally identified.
Magnetic resonance imaging
Single embryo imaging was performed as described previously [15–17]. For multi-embryo imaging, we used the same 11.7 Tesla (500 MHz) vertical magnet (Magnex Scientific, Oxon, UK). This was interfaced to a Bruker Avance console (Bruker Medical, Ettlingen, Germany) equipped with a shielded gradient system with a maximal gradient strength of 548 mTesla/m (Magnex Scientific, Oxon, UK), and quadrature-driven birdcage type coils with an inner diameter of 28 mm (Rapid Biomedical, Würzburg, Germany). Compressed air at room temperature was used to reduce the heating induced by the gradients. A 3D spoiled gradient echo sequence (echo time 10 ms), a π/2 excitation pulse with rectangular pulse shape, (π/2 = 100 μs), was used with a short repetition time (30 ms) to obtain strong T1 contrast. A matrix size of 512 × 512 × 768 (bandwidth: 130 Hz/pixel) at a field of view of 26 × 26 × 30 mm achieved an experimental resolution of 51 × 51 × 39 μm when imaging up to 16 specimens. In case of 32 embryos, a matrix size of 608 × 608 × 1408 at field of view of 26 × 26 × 50 mm, yielded an experimental resolution of 43 × 43 × 36 μm. The total experimental time was ~8.75 hours for 16 embryos, and ~12.3 hours for 32 embryos (typically overnight runs) whereby each phase encoding step was averaged four times.
Data reconstruction and analysis
The raw MR data were reconstructed into a stack of 1024 (for 16 embryos), or 2048 (for 32 embryos) 2D TIFF files (16 bit pixel resolution, 2 or 4 GB total size) using purpose-written software as described previously . The TIFF files were analyzed using Amira 3.1(TGS Europe, Mérignac Cedex, France). 3D reconstructions were performed using the Image Segmentation Editor, and tissue volumes for morphometric analysis were measured using the Measure Tissue Statistics tool available in Amira 3.1. The probability (p) of a Type I error was calculated using a 2-sample equal variance 2-tailed t-test in Microsoft Excel.
Embryos were dehydrated in ethanol, embedded in paraffin wax, and sections were stained with hematoxylin and eosin.
X-Gal staining of embryos
Embryos were dissected free of extraembryonic membranes and then fixed in 4% paraformaldehyde at 4°C. Expression of Ptdsr was detected by staining the embryos overnight in X-Gal according to standard protocols. The embryos were postfixed in 4% paraformaldehyde and processed for documentation or histology.
We thank Tim Bardsley and Neil Hoggarth for help with information technology, and Titus Lanz (Rapid Biomedical) for developing the MR probe. These studies were funded by the Wellcome Trust, British Heart Foundation, and the EU project EUMORPHIA (QLG2-CT-2002-00930). S.B. is a Wellcome Trust Senior Fellow in Clinical Science.
- Srivastava D: Congenital heart defects: trapping the genetic culprits. Circ Res. 2000, 86: 917-918.View ArticlePubMedGoogle Scholar
- Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, Maron BJ, Seidman CE, Seidman JG: Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science. 1998, 281: 108-111. 10.1126/science.281.5373.108.View ArticlePubMedGoogle Scholar
- Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K, Matsuoka R, Cohen JC, Srivastava D: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 2003, 424: 443-447. 10.1038/nature01827.View ArticlePubMedGoogle Scholar
- Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer M, Seidman CE, Seidman JG: A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell. 2001, 106: 709-721. 10.1016/S0092-8674(01)00493-7.View ArticlePubMedGoogle Scholar
- Mansour SL, Thomas KR, Capecchi MR: Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature. 1988, 336: 348-352. 10.1038/336348a0.View ArticlePubMedGoogle Scholar
- Stanford WL, Cohn JB, Cordes SP: Gene-trap mutagenesis: past, present and beyond. Nat Rev Genet. 2001, 2: 756-768. 10.1038/35093548.View ArticlePubMedGoogle Scholar
- Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet. 2000, 25: 35-41. 10.1038/75568.View ArticlePubMedGoogle Scholar
- Nolan PM, Peters J, Strivens M, Rogers D, Hagan J, Spurr N, Gray IC, Vizor L, Brooker D, Whitehill E, Washbourne R, Hough T, Greenaway S, Hewitt M, Liu X, McCormack S, Pickford K, Selley R, Wells C, Tymowska-Lalanne Z, Roby P, Glenister P, Thornton C, Thaung C, Stevenson JA, Arkell R, Mburu P, Hardisty R, Kiernan A, Erven A, Steel KP, Voegeling S, Guenet JL, Nickols C, Sadri R, Nasse M, Isaacs A, Davies K, Browne M, Fisher EM, Martin J, Rastan S, Brown SD, Hunter J: A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet. 2000, 25: 440-443. 10.1038/78140.View ArticlePubMedGoogle Scholar
- Hrabe de Angelis MH, Flaswinkel H, Fuchs H, Rathkolb B, Soewarto D, Marschall S, Heffner S, Pargent W, Wuensch K, Jung M, Reis A, Richter T, Alessandrini F, Jakob T, Fuchs E, Kolb H, Kremmer E, Schaeble K, Rollinski B, Roscher A, Peters C, Meitinger T, Strom T, Steckler T, Holsboer F, Klopstock T, Gekeler F, Schindewolf C, Jung T, Avraham K, Behrendt H, Ring J, Zimmer A, Schughart K, Pfeffer K, Wolf E, Balling R: Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet. 2000, 25: 444-447. 10.1038/78146.View ArticlePubMedGoogle Scholar
- Balling R: ENU mutagenesis: analyzing gene function in mice. Annu Rev Genomics Hum Genet. 2001, 2: 463-492. 10.1146/annurev.genom.2.1.463.View ArticlePubMedGoogle Scholar
- Nadeau JH, Balling R, Barsh G, Beier D, Brown SD, Bucan M, Camper S, Carlson G, Copeland N, Eppig J, Fletcher C, Frankel WN, Ganten D, Goldowitz D, Goodnow C, Guenet JL, Hicks G, Hrabe de Angelis M, Jackson I, Jacob HJ, Jenkins N, Johnson D, Justice M, Kay S, Kingsley D, Lehrach H, Magnuson T, Meisler M, Poustka A, Rinchik EM, Rossant J, Russell LB, Schimenti J, Shiroishi T, Skarnes WC, Soriano P, Stanford W, Takahashi JS, Wurst W, Zimmer A: Sequence interpretation. Functional annotation of mouse genome sequences. Science. 2001, 291: 1251-1255. 10.1126/science.1058244.View ArticlePubMedGoogle Scholar
- Austin CP, Battey JF, Bradley A, Bucan M, Capecchi M, Collins FS, Dove WF, Duyk G, Dymecki S, Eppig JT, Grieder FB, Heintz N, Hicks G, Insel TR, Joyner A, Koller BH, Lloyd KC, Magnuson T, Moore MW, Nagy A, Pollock JD, Roses AD, Sands AT, Seed B, Skarnes WC, Snoddy J, Soriano P, Stewart DJ, Stewart F, Stillman B, Varmus H, Varticovski L, Verma IM, Vogt TF, von Melchner H, Witkowski J, Woychik RP, Wurst W, Yancopoulos GD, Young SG, Zambrowicz B: The knockout mouse project. Nat Genet. 2004, 36: 921-924. 10.1038/ng0904-921.PubMed CentralView ArticlePubMedGoogle Scholar
- Auwerx J, Avner P, Baldock R, Ballabio A, Balling R, Barbacid M, Berns A, Bradley A, Brown S, Carmeliet P, Chambon P, Cox R, Davidson D, Davies K, Duboule D, Forejt J, Granucci F, Hastie N, de Angelis MH, Jackson I, Kioussis D, Kollias G, Lathrop M, Lendahl U, Malumbres M, von Melchner H, Muller W, Partanen J, Ricciardi-Castagnoli P, Rigby P, Rosen B, Rosenthal N, Skarnes B, Stewart AF, Thornton J, Tocchini-Valentini G, Wagner E, Wahli W, Wurst W: The European dimension for the mouse genome mutagenesis program. Nat Genet. 2004, 36: 925-927. 10.1038/ng0904-925.PubMed CentralView ArticlePubMedGoogle Scholar
- Brown SD, Balling R: Systematic approaches to mouse mutagenesis. Curr Opin Genet Dev. 2001, 11: 268-273. 10.1016/S0959-437X(00)00189-1.View ArticlePubMedGoogle Scholar
- Schneider JE, Bamforth SD, Farthing CR, Clarke K, Neubauer S, Bhattacharya S: High-resolution imaging of normal anatomy, and neural and adrenal malformations in mouse embryos using magnetic resonance microscopy. J Anat. 2003, 202: 239-247. 10.1046/j.1469-7580.2003.00157.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Schneider JE, Bamforth SD, Grieve SM, Clarke K, Bhattacharya S, Neubauer S: High-resolution, high-throughput magnetic paragraph sign resonance imaging of mouse embryonic paragraph sign anatomy using a fast gradient-echo sequence. Magma. 2003, 16: 43-51.View ArticlePubMedGoogle Scholar
- Schneider JE, Bamforth SD, Farthing CR, Clarke K, Neubauer S, Bhattacharya S: Rapid identification and 3D reconstruction of complex cardiac malformations in transgenic mouse embryos using fast gradient echo sequence magnetic resonance imaging. J Mol Cell Cardiol. 2003, 35: 217-222. 10.1016/S0022-2828(02)00291-2.View ArticlePubMedGoogle Scholar
- Herron BJ, Lu W, Rao C, Liu S, Peters H, Bronson RT, Justice MJ, McDonald JD, Beier DR: Efficient generation and mapping of recessive developmental mutations using ENU mutagenesis. Nat Genet. 2002, 30: 185-189. 10.1038/ng812.View ArticlePubMedGoogle Scholar
- Bamforth SD, Braganca J, Eloranta JJ, Murdoch JN, Marques FI, Kranc KR, Farza H, Henderson DJ, Hurst HC, Bhattacharya S: Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat Genet. 2001, 29: 469-474. 10.1038/ng768.View ArticlePubMedGoogle Scholar
- Kranc KR, Bamforth SD, Braganca J, Norbury C, van Lohuizen M, Bhattacharya S: Transcriptional coactivator Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation via Ink4a/ARF. Mol Cell Biol. 2003, 23: 7658-7666. 10.1128/MCB.23.21.7658-7666.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Böse J, Gruber AD, Helming L, Schiebe S, Wegener I, Hafner M, Beales M, Kontgen F, Lengeling A: The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. J Biol. 2004, 3: 15-10.1186/jbiol10.PubMed CentralView ArticlePubMedGoogle Scholar
- Li MO, Sarkisian MR, Mehal WZ, Rakic P, Flavell RA: Phosphatidylserine receptor is required for clearance of apoptotic cells. Science. 2003, 302: 1560-1563. 10.1126/science.1087621.View ArticlePubMedGoogle Scholar
- Cui P, Qin B, Liu N, Pan G, Pei D: Nuclear localization of the phosphatidylserine receptor protein via multiple nuclear localization signals. Exp Cell Res. 2004, 293: 154-163. 10.1016/j.yexcr.2003.09.023.View ArticlePubMedGoogle Scholar
- Kunisaki Y, Masuko S, Noda M, Inayoshi A, Sanui T, Harada M, Sasazuki T, Fukui Y: Defective fetal liver erythropoiesis and T-lymphopoiesis in mice lacking phosphatidylserine receptor. Blood. 2004, 103: 3362-3364. 10.1182/blood-2003-09-3245.View ArticlePubMedGoogle Scholar
- Shou W, Aghdasi B, Armstrong DL, Guo Q, Bao S, Charng MJ, Mathews LM, Schneider MD, Hamilton SL, Matzuk MM: Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature. 1998, 391: 489-492. 10.1038/35146.View ArticlePubMedGoogle Scholar
- Schwenk F, Baron U, Rajewsky K: A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995, 23: 5080-5081.PubMed CentralView ArticlePubMedGoogle Scholar
- Matsuda Y, Utsuzawa S, Kurimoto T, Haishi T, Yamazaki Y, Kose K, Anno I, Marutani M: Super-parallel MR microscope. Magn Reson Med. 2003, 50: 183-189. 10.1002/mrm.10515.View ArticlePubMedGoogle Scholar
- Bock NA, Konyer NB, Henkelman RM: Multiple-mouse MRI. Magn Reson Med. 2003, 49: 158-167. 10.1002/mrm.10326.View ArticlePubMedGoogle Scholar
- Kirby ML: Contribution of neural crest to heart and vessel morphology. Heart development. Edited by: Harvey RP and Rosenthal N. 1999, San Diego, Academic PressGoogle Scholar
- Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994, 4: 1-7. 10.1016/S0960-9822(00)00002-6.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.